NCT01520220

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms.

Conditions

• Myeloproliferative Neoplasms of
• Polycythemia Vera
• Essential Thrombocythemia
• Myelofibrosis

Interventions

Type	Name	Description
DRUG	LY2784544	LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.

Timeline

• Start date: 2012-06-11
• Primary completion: 2015-06-26
• Completion: 2017-02-24
• First posted: 2012-01-27
• Last updated: 2017-04-12

Locations

9 sites across 1 country: United States